Internal Medicine, Medical Oncology · Grand Rapids, MI
NPI
1982867891
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
250 Cherry St SE Ste 2200
Grand Rapids, MI, 49503
Phone (616) 685-5600
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
56,680 services
Medicare patients, 2024
331
Average age 73
Drug cost, 2024
$7.2M
1,251 prescriptions
Company payments, 2025
$359
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jared D Knol was code J9271 (injection, pembrolizumab, 1 mg), 8,000 times for 11 patients. In total Jared D Knol billed 56,680 services in 151 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 8,000 | 11 | $44.84 | $359K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,524 | 39 | $0.09 | $130 |
| 36415 Venipuncture Blood Collection | Office | 610 | 114 | $8.62 | $5,260 |
| 85025 Blood Count | Office | 509 | 96 | $7.60 | $3,867 |
| 80053 Clinical Chemistry | Office | 479 | 99 | $10.30 | $4,934 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 440 | 12 | $0.68 | $299 |
| 99214 Office E&M - Established | Office | 233 | 119 | $91.80 | $21K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 223 | 30 | $140.06 | $31K |
| 96375 Injection Administration | Office | 215 | 39 | $11.05 | $2,377 |
| 96413 Chemotherapy Administration | Office | 207 | 52 | $91.24 | $19K |
| 99213 Office E&M - Established | Office | 178 | 113 | $59.05 | $11K |
| 84153 Clinical Chemistry | Office | 156 | 51 | $17.73 | $2,765 |
| 83735 Clinical Chemistry | Office | 129 | 29 | $6.57 | $848 |
| J7030 Infusion, normal saline solution , 1000 cc | Office | 124 | 29 | $1.99 | $247 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 108 | 13 | $4.70 | $508 |
By year: 2022 $2.7M for 122,085 services; 2023 $1.6M for 73,888 services; 2024 $1.2M for 56,680 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 610 | 114 | $8.62 | $5,260 |
| 85025 Blood Count | 509 | 96 | $7.60 | $3,867 |
| 80053 Clinical Chemistry | 479 | 99 | $10.30 | $4,934 |
| 84153 Clinical Chemistry | 156 | 51 | $17.73 | $2,765 |
| 83735 Clinical Chemistry | 129 | 29 | $6.57 | $848 |
| 84443 Clinical Chemistry | 86 | 25 | $16.46 | $1,416 |
| 84403 Clinical Chemistry | 49 | 30 | $24.85 | $1,218 |
| 84439 Clinical Chemistry | 22 | 12 | $8.84 | $194 |
| 86704 Immunoassay | 22 | 22 | $11.81 | $260 |
| 86706 Immunoassay | 22 | 22 | $10.53 | $232 |
Medicare prescription drug claims, 2024
In 2024, the drug Jared D Knol prescribed most often to Medicare patients was Xtandi (Enzalutamide), with 205 prescriptions and refills. In total Jared D Knol wrote 1,251 Medicare prescriptions that cost $7.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | 205 | 205 | 29 | $2.0M |
| Prednisone Generic | 179 | 186 | 57 | $540 |
| Abiraterone Acetate Generic | 94 | 94 | 22 | $224K |
| Prochlorperazine Maleate Generic | 89 | 89 | 63 | $1,087 |
| Cabometyx Cabozantinib S-Malate | 78 | 78 | 16 | $1.7M |
| Bicalutamide Generic | 49 | 57 | 34 | $585 |
| Lenvima Lenvatinib Mesylate | 48 | 48 | 15 | $986K |
| Levothyroxine Sodium Generic | 48 | 72 | 11 | $368 |
| Welireg Belzutifan | 45 | 45 | 11 | $1.1M |
| Ondansetron Hcl Generic | 40 | 40 | 15 | $451 |
| Everolimus Generic | 35 | 35 | Under 11 | $183K |
| Olanzapine Generic | 33 | 34 | 23 | $128 |
| Ondansetron Odt Ondansetron | 32 | 32 | 15 | $646 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 25 | 25 | 18 | $331 |
| Inlyta Axitinib | 24 | 24 | Under 11 | $424K |
Brand drugs: 514 claims; generic drugs: 737 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jared D Knol $359 ($359 in general payments such as food, travel and fees) from 9 companies. The largest payer was Merck Sharp & Dohme LLC with $92.52.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 3 | $92.52 |
| Shorla Oncology Inc. | 1 | $71.2 |
| SpringWorks Therapeutics, Inc. | 2 | $40.85 |
| Agios Pharmaceuticals, Inc. AGIO | 1 | $33.7 |
| Astellas Pharma US Inc 4503.T | 1 | $28.87 |
| Kite Pharma, Inc. GILD | 1 | $27.69 |
| GlaxoSmithKline, LLC. GSK | 1 | $26.5 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $21.97 |
| Pfizer Inc. PFE | 1 | $15.75 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.